Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children

Vaccine

Volumn 28, Issue 30, 2010, Pages 4798-4801

  Bian, Guo Lin ^a   Ma, Rui ^a   Dong, Hong Jun ^a   Ni, Hong Xia ^a   Hu, Feng Jiao ^a   Chen, Yao rong ^a   Chen, Jia Qun ^a   Zhou, Shao Ying ^a   Lin, Yong Xin ^a   Xu, Guo Zhang ^a  

^a NINGBO MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Hepatitis A vaccine; Immunogenicity; Long term follow up

Indexed keywords

HEPATITIS A VACCINE; INACTIVATED VIRUS VACCINE; HEPATITIS A ANTIBODY; INACTIVATED VACCINE; LIVE VACCINE; VIRUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; FOLLOW UP; HEALTH STATUS; HEPATITIS A; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; CHILD; CHINA; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGY; FEMALE; IMMUNOLOGY; INFANT; MALE; PRESCHOOL CHILD; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VACCINATION;

ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CHINA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MALE; MODELS, STATISTICAL; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 77954212742     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.096     Document Type: Article

References (22)

1. World Health Organization Hepatitis A vaccines WHO position paper. Wkly Epidemiol Rec 2000, 75:38-44.
2. Armstrong G.L., Bell B.P. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 2002, 109:839-845.
3. Van Damme P., Van Herck K. Effect of hepatitis A vaccination programs. JAMA 2005, 294:246-248.
4. Black S., Shinefield H., Hansen J., Lewis E., Su L., Coplan P. A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA, Merck) in children and adults. Vaccine 2004, 22:766-772.
5. Bell B.P., Feinstone S.M. Hepatitis A vaccine. Vaccines 2004, 269-297. WB Saunders Co., Philadelphia. 4th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
6. Huang D.B., Wu J.J., Tyring S.K. A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J Infect 2004, 49:179-209.
7. Van Damme P., Banatvala J., Fay O., Iwarson S., McMahon B., Van Herck K., et al. Hepatitis A booster vaccination: is there a need?. Lancet 2003, 362:1065-1071.
8. Van Herck K., Van Damme P. Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines 2005, 4:459-471.
9. Mao J.S., Chai S.A., Xie R.Y., Chen N.L., Jiang Q., Zhu X.Z., et al. Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans. Vaccine 1997, 15:944-947.
10. Van Herck K., Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow up and estimates of long term persistence. J Med Virol 2001, 63:1-7.
11. Fan P.C., Chang M.H., Lee P.I., Safary A., Lee C.Y. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine 1998, 16:232-235.
12. Rendi-Wagner P., Korinek M., Winkler B., Kundi M., Kollaritsch H., Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 2007, 25:927-931.
13. Bryan J.P., Henry C.H., Hoffman A.G., South-Paul J.E., Smith J.A., Cruess D., et al. Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 2001, 19:743-750.
14. Braconier J.H., Wennerholm S., Norrby S.R. Comparative immunogenicity and tolerance of Vaqta™ and Havrix™. Vaccine 1999, 17:2181-2184.
15. Ashur Y., Adler R., Rowe M., Shouval D. Comparison of immunogenicity of two hepatitis A vaccines - VAQTA and HAVRIX - in young adults. Vaccine 1999, 17:2290-2296.
16. Van Herck K., Beutels P., Van Damme P., Beutels M., Van den Dries J., Briantais P., et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 2000, 60:1-7.
17. Cederna B.K., Klinzman D., Stapleton J.T. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine 2000, 18:892-898.
18. Wang X.Y., Xu Z., Yao X., Tian M., Zhou L., He L., et al. Immune responses of anti-HAV in children vaccinated with live attenuated and inactivated hepatitis A vaccines. Vaccine 2004, 22:1941-1945.
19. Gilljam G., Wahren B. Properties of IgG subclasses to human cytomegalovirus. J Virol Meth 1989, 25(2):139-151.
20. Urban M., Winkler T., Landini M.P., Britt W., Mach M. Epitope-specific distribution of IgG subclasses against antigenic domains on glycoproteins of human cytomegalovirus. J Infect Dis 1994, 169(1):83-90.
21. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383(6603):787-793.
22. Wang X.Y., Xu Z.Y., Ma J.C., von Seidlein L., Zhang Y., Hao Z.Y., et al. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up. Vaccine 2007, 3:446-449.